Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation

Meng Tian

doi:10.1016/j.phymed.2026.158272

Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation

2026-05-04

0

PRE

AI

M

Meng Tian

X

Xiaoyu Li

J

Jue Yang

X

Xiuyun Bai

R

Rongjun Deng

W

Wanting Ye

Q

Qiqiong Liu

Y

Ying Xing

Y

Yuxing Yao

C

Cheng Lü *

Y

Yuanyan Liu *

DOI：10.1016/j.phymed.2026.158272

Original

Original request for help

Save

Abstract

En 中文

Triple-negative breast cancer (TNBC) exhibits the highest level of immunogenicity among breast cancer subtypes, making it particularly responsive to immunotherapy due to tumor immune infiltration and elevated expression of immune markers. Atezolizumab, an important PD-L1 inhibitor, may reduce immunosuppressive signals by blocking PD-L1/PD-1 binding but is limited by its off-target and high cost. Glycosylation, as a key post-translational modification, is recognized for its significant role in regulating PD-L1 protein stability, which in turn promotes PD-L1/PD-1 interaction and facilitates immune evasion. Ginsenoside Rg3 is a bio-active ingredient derived from the traditional Chinese herb ginseng that exerts an acknowledged immunomodulatory effect.

Keywords:

Ginsenoside Rg3

Atezolizumab

Triple-negative breast cancer

PD-L1

Glycosylation

Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation

Abstract

Journal

Organization

Cited Papers

Citing Papers